origin_datas.zip

<b><i>Background</i></b><b>: </b>Colorectal cancer (CRC) is a popular malignancy with highly incidence in developed countries. In this study, we aimed to explore the N6-methyladenosine (m6A) regulators-related prognosis signatures in CRC progression.<b><i>Method</i></b>: The bulk RNA-seq data of AC-ICAM and GSE33113 database of CRC were obtained from the cBioportal and GEO database, and 21 m6A regulators genes was used for this study. The Seurat and harmony R package were used for the scRNA-seq analysis of GSE146771 cohort. The ConsensusClusterPlus package performed the consensus clustering based on the m6A regulators expression. The ggGSEA package was used for the Gene Set Enrichment Analysis (GSEA). The un/multivariate and lasso Cox analysis was performed by the “survival” and “glmnet” for risk model construction. The pRRophetic and GSVA package was used for the potential drugs and immune infiltration analysis, and the KM survival and ROC analysis was performed through the “survival” and “timeROC” package. The vitro assay including the qPCR, wound healing and trans-well were formed.<b><i>Results</i></b>: The patients in the AC-ICAM cohort were divided into three molecular subtypes (S1, 2 and 3) based on 9 m6A regulators prognostic genes, the S3 had the significantly good outcome, while the S1 was the poorest prognosis and associated with the activation of NF-kB, TNF-α and Hypoxia pathways. Subsequently, we determined 3 key genes for the RiskScore from the above 9 m6A regulators genes, the RiskScore system with good classification effectiveness divided the patients into high and low risk groups, in which the former had more types of immune cell infiltration that supported multiple immune response activation and exhibited significantly poor prognosis, the <i>METTL3</i> is a key risk factor for migration and invasion of CRC. Meanwhile, a nomogram with highly clinical practical value was developed based in the RiskScore and other clinical features. Finally, 8 potential drugs associated with the RiskScore were identified and CD4+ cells and the Tregs were associated with the cancer progression.<b><i>Conclusion</i></b>: We identified the m6A regulators-signature as a reliable prognostic phenotype and developed a useful m6A regulators-related RiskScore for the prognosis of CRC patients.